论文部分内容阅读
在发展脂质体包裹抗癌药物方面已取得进展。美国Ontario 地区癌症中心和Roswell 公园纪念研究所共同进行的试验,已用逐步增加剂量的DOX-99治疗肿瘤患者,DOX-99是脂质体公司(TLC)研制的用脂质体包裹的阿霉素。使用时,只在少数病例中观察到轻度白细胞降低,改变剂量并不能防止它。同时,使用阿霉素常见的恶心、呕吐或脱发现象即使偶尔遇见症状也较轻。DOX-99最常见的副作用是大约一半病人中特别是老年病例中有持续数日至一周的不适。约一半病例有发热,有时伴随着寒战,但这很容易治疗。通过1h 灌注可控制由于注射太快而引起的大量出汗等中毒症状。DOX-99不仅安全而且更有效,它容易
Progress has been made in the development of liposome-encapsulated anti-cancer drugs. The trial, conducted jointly by the Ontario Regional Cancer Center in the United States and the Roswell Park Memorial Institute, has been used to treat tumor patients with escalating doses of DOX-99, a liposome-coated, Prime When used, only a small number of cases observed in mild leukopenia, change the dose and can not prevent it. At the same time, the common use of doxorubicin nausea, vomiting or hair loss even if the symptoms encountered occasionally lighter. The most common side effect of DOX-99 is discomfort lasting from a few days to a week in about one-half of patients, especially in elderly cases. About half of cases have fever, sometimes accompanied by chills, but this is easy to treat. By 1h perfusion can be controlled due to injection too fast and cause a lot of sweating and other symptoms of poisoning. DOX-99 is not only safe but also more effective, it’s easy